ACR Urges HHS to Promote Annual Lung Cancer Screenings
In a recent comment letter, the College presented updated data that highlights the life-saving potential of lung cancer screening.
Read moreMain Content
ACR Recommends Tariff Deferrals for Contrast Media
ACR also recommends tariff Deferrals for Radiopharmaceuticals
May 15, 2025
The American College of Radiology® (ACR®) filed comments May 7, with the U.S. Department of Commerce recommending that contrast media and radiopharmaceuticals be excluded or deferred from tariff impacts until greater domestic supplies are available.
ACR’s comments were in response to a request for comments regarding Section 232 national security investigation of pharmaceuticals and ingredients issued by Commerce’s Bureau of Industry and Security (BIS). Section 232 allows the imposition of tariffs on imports that threaten national security. Pharmaceuticals and pharmaceutical ingredients are among several topics being considered by BIS.
The College indicated that contrast media and radiopharmaceuticals are integral components of medical procedures administered by qualified healthcare providers, often without alternative products, and should therefore be excluded or deferred.
For questions, contact Michael Peters, ACR Senior Director, Government Affairs.
Related ACR News
FDA Approves Alternative Standard Breast Density Reporting
The Alternative Standard will allow the physician to provide an overall assessment of breast density with singular phrasing in reports of unilateral mammograms.
Read moreState-Radiology Bills Report Card
An update on radiology-specific state legislation that ACR is tracking. This report focuses on scope of practice.
Read more